This webinar looks at the factors that influence multinational pharmaceutical companies to consider a partnership with Australian businesses to run their first-in-human trials.
TORONTO (PRWEB) October 09, 2020
Australia has rapidly become a key proving ground in the clinical trial sector. With a diverse population, world-class medical research facilities and considerable cost advantages, this webinar looks at the factors t- hat influence multinational pharmaceutical companies to consider a partnership with Australian businesses to run their first-in-human trials.
GABA Therapeutics is developing an innovative compound with the potential to transform the lives of patients with life-altering neuropsychiatric, neurologic and pain disorders. With Cosec aiding their operations in Australia and partnering with Nucleus Network and 360BioLabs for the clinical trial, this discussion will include client insight into the decisions, challenges and results of selecting Australia as a first-in-human trial location.
For more information or to register for this event, visit 7,300 miles: Why California’s Gaba Therapeutics Conducted Clinical Trials in Australia.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.